Annual SG&A
$112.88 M
-$23.60 M-17.29%
31 December 2023
Summary:
Vanda Pharmaceuticals annual selling, general & administrative expenses is currently $112.88 million, with the most recent change of -$23.60 million (-17.29%) on 31 December 2023. During the last 3 years, it has fallen by -$27.63 million (-19.66%). VNDA annual SG&A is now -19.66% below its all-time high of $140.51 million, reached on 31 December 2020.VNDA Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$37.57 M
-$1.90 M-4.82%
30 September 2024
Summary:
Vanda Pharmaceuticals quarterly selling, general & administrative expenses is currently $37.57 million, with the most recent change of -$1.90 million (-4.82%) on 30 September 2024. Over the past year, it has increased by +$12.81 million (+51.71%). VNDA quarterly SG&A is now -8.02% below its all-time high of $40.85 million, reached on 31 March 2022.VNDA Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$648.37 M
-$16.39 M-2.59%
30 September 2024
Summary:
Vanda Pharmaceuticals TTM selling, general & administrative expenses is currently -$648.37 million, with the most recent change of -$16.39 million (-2.59%) on 30 September 2024. Over the past year, it has dropped by -$770.42 million (-631.22%). VNDA TTM SG&A is now -1684.69% below its all-time high of $141.96 million, reached on 30 September 2020.VNDA TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VNDA Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -17.3% | +51.7% | -631.2% |
| 3 y3 years | -19.7% | +15.8% | -613.9% |
| 5 y5 years | +6.7% | +24.3% | -651.1% |
VNDA Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -19.7% | at low | -8.0% | +59.1% | -5.2% | +11.9% |
| 5 y | 5 years | -19.7% | +6.7% | -8.0% | +59.1% | -5.2% | +47.0% |
| alltime | all time | -19.7% | +5226.2% | -8.0% | +2156.8% | -1684.7% | +54.8% |
Vanda Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $37.57 M(-4.8%) | $130.75 M(+10.9%) |
| June 2024 | - | $39.47 M(+31.2%) | $117.94 M(+10.4%) |
| Mar 2024 | - | $30.09 M(+27.4%) | $106.86 M(-5.3%) |
| Dec 2023 | $112.88 M(-17.3%) | $23.61 M(-4.7%) | $112.88 M(-7.5%) |
| Sept 2023 | - | $24.77 M(-12.8%) | $122.05 M(-4.0%) |
| June 2023 | - | $28.40 M(-21.3%) | $127.14 M(-3.5%) |
| Mar 2023 | - | $36.10 M(+10.1%) | $131.74 M(-3.5%) |
| Dec 2022 | $136.49 M(+10.0%) | $32.78 M(+9.8%) | $136.49 M(-0.5%) |
| Sept 2022 | - | $29.85 M(-9.5%) | $137.15 M(-1.9%) |
| June 2022 | - | $33.00 M(-19.2%) | $139.75 M(+3.4%) |
| Mar 2022 | - | $40.85 M(+22.1%) | $135.10 M(+8.9%) |
| Dec 2021 | $124.05 M(-11.7%) | $33.45 M(+3.1%) | $124.05 M(-1.7%) |
| Sept 2021 | - | $32.46 M(+14.5%) | $126.17 M(-1.2%) |
| June 2021 | - | $28.35 M(-4.9%) | $127.72 M(-4.2%) |
| Mar 2021 | - | $29.80 M(-16.2%) | $133.29 M(-5.1%) |
| Dec 2020 | $140.51 M(+8.3%) | $35.57 M(+4.6%) | $140.51 M(-1.0%) |
| Sept 2020 | - | $34.00 M(+0.2%) | $141.96 M(+2.7%) |
| June 2020 | - | $33.92 M(-8.4%) | $138.18 M(+1.8%) |
| Mar 2020 | - | $37.02 M(+0.0%) | $135.73 M(+4.6%) |
| Dec 2019 | $129.74 M(+22.7%) | $37.02 M(+22.5%) | $129.74 M(+10.3%) |
| Sept 2019 | - | $30.22 M(-4.0%) | $117.64 M(+3.7%) |
| June 2019 | - | $31.47 M(+1.4%) | $113.47 M(+3.2%) |
| Mar 2019 | - | $31.03 M(+24.5%) | $109.96 M(+4.0%) |
| Dec 2018 | $105.75 M(-14.6%) | $24.92 M(-4.3%) | $105.75 M(-5.5%) |
| Sept 2018 | - | $26.05 M(-6.8%) | $111.88 M(-4.3%) |
| June 2018 | - | $27.96 M(+4.2%) | $116.95 M(-2.8%) |
| Mar 2018 | - | $26.82 M(-13.6%) | $120.37 M(-2.8%) |
| Dec 2017 | $123.84 M(+24.1%) | $31.05 M(-0.2%) | $123.84 M(+6.1%) |
| Sept 2017 | - | $31.12 M(-0.8%) | $116.70 M(+8.6%) |
| June 2017 | - | $31.37 M(+3.5%) | $107.48 M(+6.6%) |
| Mar 2017 | - | $30.30 M(+26.7%) | $100.79 M(+1.0%) |
| Dec 2016 | $99.79 M(+18.0%) | $23.91 M(+9.1%) | $99.79 M(-4.7%) |
| Sept 2016 | - | $21.91 M(-11.2%) | $104.76 M(+3.4%) |
| June 2016 | - | $24.68 M(-15.7%) | $101.31 M(+6.6%) |
| Mar 2016 | - | $29.29 M(+1.4%) | $95.02 M(+12.4%) |
| Dec 2015 | $84.53 M(-0.1%) | $28.88 M(+56.5%) | $84.53 M(+15.8%) |
| Sept 2015 | - | $18.46 M(+0.4%) | $72.97 M(+10.9%) |
| June 2015 | - | $18.39 M(-2.2%) | $65.81 M(-12.9%) |
| Mar 2015 | - | $18.81 M(+8.6%) | $75.56 M(-10.7%) |
| Dec 2014 | $84.64 M | $17.32 M(+53.4%) | $84.64 M(+9.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2014 | - | $11.29 M(-59.9%) | $77.25 M(+7.7%) |
| June 2014 | - | $28.14 M(+0.9%) | $71.70 M(+46.9%) |
| Mar 2014 | - | $27.89 M(+181.0%) | $48.82 M(+94.6%) |
| Dec 2013 | $25.08 M(+72.8%) | $9.93 M(+72.9%) | $25.08 M(+31.9%) |
| Sept 2013 | - | $5.74 M(+9.1%) | $19.01 M(+15.8%) |
| June 2013 | - | $5.26 M(+26.7%) | $16.42 M(+11.2%) |
| Mar 2013 | - | $4.15 M(+7.6%) | $14.76 M(+1.7%) |
| Dec 2012 | $14.52 M(+26.4%) | $3.86 M(+22.7%) | $14.52 M(+3.7%) |
| Sept 2012 | - | $3.15 M(-12.6%) | $14.00 M(+3.2%) |
| June 2012 | - | $3.60 M(-7.9%) | $13.57 M(+8.2%) |
| Mar 2012 | - | $3.91 M(+16.9%) | $12.54 M(+9.2%) |
| Dec 2011 | $11.49 M(+13.2%) | $3.35 M(+23.4%) | $11.49 M(+5.3%) |
| Sept 2011 | - | $2.71 M(+5.4%) | $10.90 M(+6.4%) |
| June 2011 | - | $2.57 M(-10.0%) | $10.25 M(-2.6%) |
| Mar 2011 | - | $2.86 M(+3.5%) | $10.52 M(+3.6%) |
| Dec 2010 | $10.15 M(-57.2%) | $2.76 M(+34.5%) | $10.15 M(-39.0%) |
| Sept 2010 | - | $2.05 M(-27.7%) | $16.63 M(-16.2%) |
| June 2010 | - | $2.84 M(+14.2%) | $19.84 M(-9.8%) |
| Mar 2010 | - | $2.49 M(-73.1%) | $21.99 M(-7.3%) |
| Dec 2009 | $23.72 M(-17.9%) | $9.25 M(+75.6%) | $23.72 M(+27.7%) |
| Sept 2009 | - | $5.27 M(+5.6%) | $18.57 M(-10.3%) |
| June 2009 | - | $4.99 M(+18.1%) | $20.71 M(-14.3%) |
| Mar 2009 | - | $4.22 M(+3.1%) | $24.17 M(-16.4%) |
| Dec 2008 | $28.91 M(-11.9%) | $4.10 M(-44.7%) | $28.91 M(-15.7%) |
| Sept 2008 | - | $7.40 M(-12.5%) | $34.29 M(-6.2%) |
| June 2008 | - | $8.46 M(-5.6%) | $36.53 M(+2.8%) |
| Mar 2008 | - | $8.96 M(-5.4%) | $35.53 M(+8.3%) |
| Dec 2007 | $32.80 M(+140.5%) | $9.47 M(-1.8%) | $32.80 M(+18.0%) |
| Sept 2007 | - | $9.65 M(+29.5%) | $27.80 M(+29.8%) |
| June 2007 | - | $7.45 M(+19.5%) | $21.41 M(+26.4%) |
| Mar 2007 | - | $6.23 M(+39.5%) | $16.95 M(+24.3%) |
| Dec 2006 | $13.64 M(+84.4%) | $4.47 M(+36.8%) | $13.64 M(+24.2%) |
| Sept 2006 | - | $3.26 M(+9.5%) | $10.98 M(+17.1%) |
| June 2006 | - | $2.98 M(+1.9%) | $9.38 M(+13.5%) |
| Mar 2006 | - | $2.92 M(+61.7%) | $8.26 M(+11.7%) |
| Dec 2005 | $7.40 M(+249.0%) | $1.81 M(+8.6%) | $7.40 M(+32.4%) |
| Sept 2005 | - | $1.66 M(-10.6%) | $5.59 M(+42.4%) |
| June 2005 | - | $1.86 M(-9.6%) | $3.92 M(+90.4%) |
| Mar 2005 | - | $2.06 M | $2.06 M |
| Dec 2004 | $2.12 M | - | - |
FAQ
- What is Vanda Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals annual SG&A year-on-year change?
- What is Vanda Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals quarterly SG&A year-on-year change?
- What is Vanda Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals TTM SG&A year-on-year change?
What is Vanda Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of VNDA is $112.88 M
What is the all time high annual SG&A for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high annual selling, general & administrative expenses is $140.51 M
What is Vanda Pharmaceuticals annual SG&A year-on-year change?
Over the past year, VNDA annual selling, general & administrative expenses has changed by -$23.60 M (-17.29%)
What is Vanda Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of VNDA is $37.57 M
What is the all time high quarterly SG&A for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $40.85 M
What is Vanda Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, VNDA quarterly selling, general & administrative expenses has changed by +$12.81 M (+51.71%)
What is Vanda Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of VNDA is -$648.37 M
What is the all time high TTM SG&A for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high TTM selling, general & administrative expenses is $141.96 M
What is Vanda Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, VNDA TTM selling, general & administrative expenses has changed by -$770.42 M (-631.22%)